A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors
Latest Information Update: 08 Oct 2024
At a glance
- Drugs ABBV-400 (Primary) ; Bevacizumab (Primary)
- Indications Acral lentiginous melanoma; Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Uterine cancer
- Focus First in man; Therapeutic Use
- Sponsors AbbVie
- 09 Sep 2024 According to an AbbVie Media Release, additional efficacy and safety data from this study will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 (September 13-17, 2024).
- 09 Sep 2024 Results presented in an AbbVie Media Release.
- 04 Jun 2024 Results (n=122, data cut-off October 2023) assessing safety and preliminary efficacy of ABBV-400 from dose escalation (ESC) and expansion (EXP) cohorts in CRC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology